Goodwin Procter LLP advised Unum Therapeutics Inc. on the deal.
Unum entered into definitive agreements for a PIPE investment with a group of institutional accredited investors led by Fairmount Funds Management LLC, with participation from Venrock Healthcare Capital Partners, BVF Partners L.P., Atlas Venture, Acorn Bioventures, Perceptive Advisor’s LLC, RTW Investments, OrbiMed, Samsara BioCapital, Logos Capital, Ally Bridge Group and Commodore Capital, as well as additional undisclosed institutional investors, to raise $104.4 million in which the investors will be issued shares of Series A Preferred Stock at a price of $880 per share (or, $0.88 per share on an as-converted-to-common basis). The PIPE offering is expected to close on July 9, 2020.
Based in Cambridge, MA, Unum Therapeutics is a biopharmaceutical company focused on developing a pipeline of novel therapies to treat cancer patients. Unum’s most advanced program, PLX9486, is a highly potent and selective KIT D816V inhibitor that is being developed to treat systemic mastocytosis and GIST patients.
The Goodwin team was led by Danielle Lauzon (Picture), and included Stephanie Richards,Nicole Daley and Kyra Ayo Caros.
Law Firms: Goodwin Procter;
Clients: Unum Therapeutics;